INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2025

The income tax provision consists of the following for the years ended December 31, 2025 and 2024:

SCHEDULE OF INCOME TAX PROVISION

	2025		2024
Federal
Current	$	-	$	-
Deferred		-		-
State and local
Current		-		-
Deferred		-		-
Foreign
Current		-		1,013
Deferred		-		-
Income tax provision / (benefit)	$	-	$	1,013

Below is a reconciliation of the statutory tax rate to the Company’s effective tax rate for the year ended December 31, 2025.

	2025
	Amount			%
Pretax book income (loss)	$	(24,480,848	)		100.0
Statutory federal income tax	$	(5,140,978	)		21.0
Research tax credits		(48,657	)		0.2
Change in valuation allowance		2,828,659			(11.5	)
Non-taxable or non-deductible items:
Non-deductible transaction costs		3,171,730			(13.0	)
Change in derivative liability		(810,787	)		3.3
Meals and entertainment		33			-
Minimum tax liability		-			-
Income tax expense	$	-			-

	2024
	Amount			%
Pretax book income (loss)	$	(1,308,859	)		100.0
Statutory federal income tax		-			-
Minimum tax liability		1,013			0.08
Income tax expense	$	1,013			0.08

The Company’s deferred tax assets are as follows at December 31, 2025 and 2024:

SCHEDULE OF DEFERRED TAX ASSETS

	2025			2024
Deferred tax assets:
Net operating loss carryforward	$	3,250,617		$	-
Research tax credit carryforward		48,657			-
Total deferred tax assets		3,299,274			-
Less: Valuation allowance		(3,299,274	)		-
Net deferred tax assets	$	-		$	-

Aspire Biopharma Holdings, Inc. 10-K/A